Management

Nils Brünner
CEO

MD, DMSc
Professor University of Copenhagen
Co-founder of Scandion Oncology A/S

Chief Financial Officer
Carit Andersen

Cand.Merc
Associate Professor
University of Southern DK

Chief Scientific Officer
Jan Stenvang, Co-founder

MSc, PhD
Associate Professor, University of Copenhagen

General Counsel
Morten Nissen

Lawyer
Gorrissen Federspiel
Former partner in global life science law firms

CMO
Peter Michael Vestlev, MD, CBA, MPP

Chief Physician, Oncologist, Region Sjælland
Previously, consultant for the Danish Medicines Agency

 

Pipeline

Scandion Oncology has two promising compounds in the pipeline, including SCO-101, which has completed four Phase I trials, and SCO-201, which is in preclinical testing stages. We aim to conclude one Phase II trial within the next 2 years. Upon conclusion of the Phase II trial, we will be ready to consider exit or partner options.

Clinical Trials

Our lead compound – SCO-101 – has been shown to enhance the effect of certain standard chemotherapy when given in combination. We are planning one Phase II trial within metastatic breast cancer. We are simultaneously developing SCO-201, which will target other solid tumors.

Investors

Detailed analyses suggests the market for Scandion Oncology’s products to be more than EUR 4 billion annually. We believe our patents could be attractive for larger pharmaceutical companies to combine with their existing cancer treatments.